A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Glecirasib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Allist Pharmaceuticals
Most Recent Events
- 04 Apr 2025 Planned primary completion date changed from 1 Dec 2023 to 1 Feb 2026.
- 06 Jan 2025 According to a Jacobio Pharmaceuticals media release, data from this study has been published in Nature Medicine.
- 21 May 2024 According to a Jacobio Pharmaceuticals media release, based upon this trial the New Drug Application (NDA) for glecirasib has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China and granted Priority Review designation, for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring KRAS G12C mutation.